Triazavirin is an antiviral agent primarily used in the treatment of viral infections such as influenza and other RNA virus infections. It works by inhibiting viral replication through interference with viral RNA synthesis. The compound has shown activity against a range of viruses, including influenza A and B, making it useful during seasonal flu outbreaks and in pandemic preparedness. It is administered orally and is valued for its relatively low toxicity and good tolerability in patients. Due to its broad-spectrum antiviral properties, it is also being studied for use in other viral diseases, particularly those caused by resistant strains. Its application is especially relevant in settings where rapid control of viral spread is critical, such as in hospitals and densely populated communities.